Pharmaceutical · Fiscal year end 8月末日

Chordia Therapeutics,Inc

190A

Ｃｈｏｒｄｉａ　Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社

FIGI BBG00R05M1F5190A.T190A JPCorp. no. 1021001063330

Latest half-year results

First half · fiscal year to 2026-08 · filed 2026-04-14

For the first half of the fiscal year to 2026-08: Ordinary income ¥-0.6 billion, Net income ¥-0.6 billion.

	This period	Year on year
Ordinary profit	−¥633m	—
Net profit to owners	−¥634m	—

From the securities report on EDINET, which states no forecast. History via /v1/companies/190A/earnings-releases.

Financials

Japan GAAP · non-consolidated · fiscal year to 2025-08-31

Revenue: —
Net income: −¥1.8bn
ROE: —
Equity ratio: 90.8%
Dividend / share: —
Employees: 20

Revenue · ¥bn

Net income · ¥bn

Fiscal year	Revenue	Net income	Total assets	Net assets	ROE	EPS	Operating CF
2025-08-31	—	−¥1,786m	¥2,681m	¥2,437m	—	¥-26.03	−¥1,837m
2024-08-31	—	−¥1,827m	¥4,632m	¥4,161m	—	¥-31.11	−¥1,937m
2023-08-31	¥2,500m	¥223m	¥4,909m	¥4,501m	5.1%	¥3.96	¥544m
2022-08-31	—	−¥1,779m	¥4,499m	¥4,278m	—	¥-39.78	−¥1,704m
2021-08-31	¥800m	−¥527m	¥2,271m	¥2,056m	—	¥-3,016.58	—

Indicators

Computed by us from filings · fiscal year to 2025-08-31

Metric	Value	Percentile among listed companies
ROE, %	—	—
Ordinary margin	—	—
Equity ratio, %	90.8	98.8
Revenue growth	—	—
Net income growth	0.0226	37.8
Operating cash flow / assets	-0.6851	0.4

Policy-uncertainty measure0.00 Share of the report's text discussing policy-related uncertainty, by policy area. Proprietary text method.

Ownership activity 0 filer(s) stated they may make proposals in 365 days; 1 new 5% holder(s) in 180 days; net stake change −3.90pt in 90 days; 17.5% held by other listed companies.

Via /v1/companies/190A/indicators. Descriptive figures, not a rating and not investment advice.

From other filings

As the company states them

Internal control, 2025-11-21: see filing 上記の評価の結果、当事業年度において取引実績のなかった事業収益及び売掛金に至る業務プロセスの有効性を除き、当社の財務報告に係る内部統制は有効であると判断しました。 Filing

Segments, votes and tender offers

Stated in EDINET filings

Latest voting result: 2025-11-25 · 取締役(監査等委員である取締役を除く。)4名選任の件 · passed. /v1/companies/190A/voting

Ownership changes

All companies →

2026-10-29

Amendment−0.70pt

Nomura Securities Co.,Ltd. filed a correction to a 5% report on Chordia Therapeutics,Inc (190A).

S100ZAMCFiler profile Original filing (PDF, Japanese)
2026-10-29

Amendment−1.24pt

Nomura Securities Co.,Ltd. filed a correction to a 5% report on Chordia Therapeutics,Inc (190A).

S100ZAMEFiler profile Original filing (PDF, Japanese)
2026-10-29

Amendment−2.06pt

Nomura Securities Co.,Ltd. filed a correction to a 5% report on Chordia Therapeutics,Inc (190A).

S100ZAMFFiler profile Original filing (PDF, Japanese)
2026-10-29

Amendment+0.66pt

Nomura Securities Co.,Ltd. filed a correction to a 5% report on Chordia Therapeutics,Inc (190A).

S100ZAMGFiler profile Original filing (PDF, Japanese)
2026-10-29

Increase+0.66pt

Nomura Securities Co.,Ltd. raised holdings in Chordia Therapeutics,Inc (190A) to 8.37% from 7.71%.

S100ZASAFiler profile Original filing (PDF, Japanese)
2026-10-29

Decrease−0.92pt

Nomura Securities Co.,Ltd. reduced holdings in Chordia Therapeutics,Inc (190A) to 7.45% from 8.37%.

S100ZASBFiler profile Original filing (PDF, Japanese)
2026-10-29

Increase+1.25pt

Nomura Securities Co.,Ltd. raised holdings in Chordia Therapeutics,Inc (190A) to 8.70% from 7.45%.

S100ZASDFiler profile Original filing (PDF, Japanese)
2026-10-29

Decrease−1.11pt

Nomura Securities Co.,Ltd. reduced holdings in Chordia Therapeutics,Inc (190A) to 7.59% from 8.70%.

S100ZASGFiler profile Original filing (PDF, Japanese)
2026-10-21

Decrease−1.15pt

Nomura Securities Co.,Ltd. reduced holdings in Chordia Therapeutics,Inc (190A) to 21.57% from 22.72%.

S100Z95JFiler profile Original filing (PDF, Japanese)
2026-10-15

Decrease−1.41pt

Nomura Securities Co.,Ltd. reduced holdings in Chordia Therapeutics,Inc (190A) to 21.40% from 22.81%.

S100Z7TOFiler profile Original filing (PDF, Japanese)

Trades by 5% holders

From the 60-day trade tables in 5% reports

Bought SoldHover a dot for the trade

Holder	Period	Net shares	Net % of shares	Avg. filed price	Range
NOMURA INTERNATIONAL PLC	2026-07-13 – 2026-10-14	-1,139,177	−1.41pt	¥71.6	¥56–86
野村證券株式会社	2026-07-21 – 2026-10-13	+17,328,300	+18.13pt	¥67.81	¥58–81
株式会社SBI証券	2024-06-14 – 2026-09-09	+8,566,000	+10.31pt	¥134.13	¥130–255
京都大学イノベーションキャピタル株式会社	2024-09-12 – 2026-05-08	-3,866,800	−5.48pt	—	—
三菱UFJキャピタル株式会社(組合名)三菱UFJライフサイエンス1号投資事業有限責任組合	2025-03-25 – 2025-04-18	-531,900	−0.75pt	—	—
ジャフコグループ株式会社	2024-09-12 – 2024-10-10	-2,394,400	−3.53pt	—	—
SMBCベンチャーキャピタル株式会社	2024-09-12 – 2024-09-26	-923,300	−1.37pt	—	—
東京大学協創プラットフォーム開発株式会社	2024-09-12 – 2024-09-19	-876,200	−1.33pt	—	—
SMBCベンチャーキャピタル株式会社	2024-09-12 – 2024-09-13	-191,100	−0.29pt	—	—
三井住友DSアセットマネジメント株式会社	2024-06-07 – 2024-06-14	+357,000	+0.55pt	¥153	¥153–153
新生キャピタルパートナーズ株式会社	2024-06-14 – 2024-06-14	+653,500	+1.00pt	¥153	¥153–153
武田薬品工業株式会社	2024-06-12 – 2024-06-12	+1,307,100	+1.99pt	¥153	¥153–153

Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/190A/trades.

5% filings

Large shareholding reports on 190A

Filed	Filer	Stake	Change	Stated purpose
2026-10-29	Nomura Securities Co.,Ltd.	4.37%	−2.06pt	—
2026-10-29	Nomura Securities Co.,Ltd.	6.43%	−1.24pt	—
2026-10-29	Nomura Securities Co.,Ltd.	7.67%	−0.70pt	—
2026-10-29	Nomura Securities Co.,Ltd.	7.59%	−1.11pt	—
2026-10-29	Nomura Securities Co.,Ltd.	8.70%	+1.25pt	—
2026-10-29	Nomura Securities Co.,Ltd.	7.45%	−0.92pt	—
2026-10-29	Nomura Securities Co.,Ltd.	8.37%	+0.66pt	—
2026-10-29	Nomura Securities Co.,Ltd.	8.37%	+0.66pt	—
2026-10-21	Nomura Securities Co.,Ltd.	21.57%	−1.15pt	—
2026-10-15	Nomura Securities Co.,Ltd.	22.72%	+1.32pt	—

Cross-shareholdings

From the annual report's status of shareholdings

Listed strategic holdings: — issues
Book value: —
Sold in the year: — — issues
Bought in the year: — — issues
Mutual, both reports: 0
Held by listed cos.: 2

Held by: Takeda Pharmaceutical Company Limited 4502, MEDIPAL HOLDINGS CORPORATION 7459

Purposes, all holdings and mutual flags via /v1/companies/190A/cross-holdings. Share changes include stock splits.

Major shareholders

As of fiscal year end 2025-08-31

Shareholder	Shares	Ratio
武田薬品工業株式会社	10,760,500	15.59%
ＮｅｗＬｉｆｅＳｃｉｅｎｃｅ１号投資事業有限責任組合	7,252,100	10.51%
日本グロースキャピタル投資法人	4,810,500	6.97%
イノベーション京都２０１６投資事業有限責任組合	4,657,700	6.75%
ＭＥＤＩＰＡＬＩｎｎｏｖａｔｉｏｎ投資事業有限責任組合	4,210,800	6.10%
三菱ＵＦＪライフサイエンス１号投資事業有限責任組合	2,971,700	4.30%
京大ベンチャーＮＶＣＣ２号投資事業有限責任組合	2,570,900	3.72%
楽天証券株式会社	1,830,400	2.65%
株式会社メディパルホールディングス	1,307,100	1.89%
individual holder	1,070,700	1.55%

Get this as JSON

GET /v1/companies/190A
GET /v1/companies/190A/financials
GET /v1/companies/190A/details
GET /v1/companies/190A/segments
GET /v1/companies/190A/voting
GET /v1/companies/190A/tender-offers
GET /v1/companies/190A/indicators
GET /v1/companies/190A/earnings-releases
GET /v1/events?ticker=190A
GET /v1/companies/190A/trades         
GET /v1/companies/190A/cross-holdings 
GET /v1/companies/190A/brief

Plans from $9 a month · Documentation